// App-Quantinova.ai

: BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).

Researchers

Presenter

  • Capucine Baldini

Principal Investigators

  • Irene Brana

  • Bernard Doger

  • Antoine Italiano

  • Sophie Cousin

  • Gerald Steven Falchook

  • Andrea Necchi

  • Oscar Reig

  • Louise Carter

  • Elisa Fontana

  • Loic Verlingue

  • Sebastien Hazard

  • Amy Dickson

  • Cong Xu

  • Hongmei Xu

  • Rajiv Sharma

  • Dominic Smethurst

  • Meredith McKean

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Quiet Therapeutics, Lexington, MA.

  • Bicycle Therapeutics Ltd, Cambridge, United Kingdom

  • Vita-Salute University, IRCCS San Raffaele Hospital, Milan, Italy

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • Léon-Bérard Centre, Lyon, France

  • START Madrid. Fundacion Jimenez Diaz, Madrid, Spain

  • Bergonie Institute, Bordeaux, France

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Sarah Cannon Research Institute, Denver, CO

  • Gustave Roussy, Villejuif, France

  • Sarah Cannon Research Institute, London, United Kingdom

  • Drug Development Department (DITEP), Gustave Roussy, Villejuif, France

Locations

  • Italy

  • France

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • monomethyl auristatin E

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04561362

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved